Literature DB >> 27889555

Correlation between microvascular dysfunction and B-type natriuretic peptide levels in non-ischemic heart failure patients with cardiac fibrosis.

Kyoko Hirakawa1, Megumi Yamamuro2, Tomoaki Uemura1, Seiji Takashio1, Koichi Kaikita1, Daisuke Utsunomiya3, Mina Nakayama1, Eiichiro Yamamoto1, Yasuyuki Yamashita3, Seiji Hokimoto1, Kenichi Tsujita1.   

Abstract

BACKGROUNDS: The relationship between microvascular dysfunction and plasma B-type natriuretic peptide (BNP) levels remains unclear in heart failure (HF) patients with cardiac fibrosis.
METHODS: This study evaluated 55 consecutive non-ischemic HF patients in an effort to determine the relationship between endothelial independent coronary microvascular dysfunction and plasma BNP levels, as well as whether each measure is correlated with myocardial fibrosis. We evaluated plasma BNP levels in patients with stable HF. We used cardiac catheterization to measure trans-cardiac BNP release levels, measuring from the coronary sinus and the aortic root, and coronary flow reserve (CFR). Patients also underwent cardiac magnetic resonance imaging to evaluate for the presence of late gadolinium enhancement (LGE), as an indicator of cardiac fibrosis.
RESULTS: CFR in cardiac catheterization was significantly and inversely correlated with plasma BNP levels (r=0.336, p=0.012) and trans-cardiac BNP release levels (r=0.347, p=0.041). Thirty-three patients were LGE-positive. CFR was significantly correlated with plasma BNP levels in the LGE-positive group (r=0.349, p=0.046), but this correlation was not significant in the LGE-negative group. (r=0.338, p=0.125). Multivariate logistic regression analysis revealed that a plasma BNP levels >180pg/ml at stable HF condition was significant and independent predictor of CFR<2.5 in all patients (p=0.035, odds ratio: 5.2, 95% confidence interval: 1.1-29.0), and in the LGE-positive group (p=0.040, odds ratio: 5.4, 95% confidence interval: 1.1-27.2).
CONCLUSIONS: In non-ischemic HF patients especially those with cardiac fibrosis, endothelial independent microvascular dysfunction is closely correlated with plasma BNP levels, and ventricular wall tension.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  B-type natriuretic peptide; Cardiac fibrosis; Coronary microvascular dysfunction; Heart failure

Mesh:

Substances:

Year:  2016        PMID: 27889555     DOI: 10.1016/j.ijcard.2016.11.054

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Chia-Ying Liu; Susan R Heckbert; Shenghan Lai; Bharath Ambale-Venkatesh; Mohammad R Ostovaneh; Robyn L McClelland; João A C Lima; David A Bluemke
Journal:  J Am Coll Cardiol       Date:  2017-12-26       Impact factor: 24.094

2.  Molecular remodeling of Cx43, but not structural remodeling, promotes arrhythmias in an arrhythmogenic canine model of nonischemic heart failure.

Authors:  Jiajie Yan; Cheryl Killingsworth; Greg Walcott; Yujie Zhu; Silvio Litovsky; Jian Huang; Xun Ai; Steven M Pogwizd
Journal:  J Mol Cell Cardiol       Date:  2021-05-31       Impact factor: 5.000

Review 3.  Role of acetylcholine spasm provocation test as a pathophysiological assessment in nonobstructive coronary artery disease.

Authors:  Satoru Suzuki; Koichi Kaikita; Eiichiro Yamamoto; Hideaki Jinnouchi; Kenichi Tsujita
Journal:  Cardiovasc Interv Ther       Date:  2020-10-27

4.  N-Terminal pro-B-type natriuretic peptide and coronary microvascular dysfunction in women with preserved ejection fraction: A report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study.

Authors:  Erika Jones; Janet Wei; Michael D Nelson; May Bakir; Puja K Mehta; Chrisandra Shufelt; Margo Minissian; Behzad Sharif; Carl J Pepine; Eileen Handberg; Galen Cook-Wiens; George Sopko; C Noel Bairey Merz
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.